A5073976413- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Chronic Myeloid Leukemia Treatments
- Hemostasis and retained surgical items
- Complement system in diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood groups and transfusion
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer-related gene regulation
- Venous Thromboembolism Diagnosis and Management
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Hemoglobinopathies and Related Disorders
- Immunotherapy and Immune Responses
- Hepatitis C virus research
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Immune Response and Inflammation
- Blood disorders and treatments
- Erythrocyte Function and Pathophysiology
- Cell Adhesion Molecules Research
- Blood properties and coagulation
CSL (United States)
2002-2024
Harvard University
1994-2024
Takeda (United States)
2016-2024
Boston Children's Hospital
1995-2024
Synta Pharmaceuticals (United States)
2022
Baxalta (United States)
2015-2021
University College London
2017
University College London Hospitals NHS Foundation Trust
2017
Baxter (United States)
2007-2016
Baxter (Austria)
2007-2013
A growing number of patients with coronary disease have refractory angina. Preclinical and early-phase clinical data suggest that intramyocardial injection autologous CD34+ cells can improve myocardial perfusion function.Evaluate the safety bioactivity injections in angina who exhausted all other treatment options.In this prospective, double-blind, randomized, phase II study (ClinicalTrials.gov identifier: NCT00300053), 167 received 1 2 doses (1×10(5) or 5×10(5) cells/kg) mobilized an equal...
Summary Objective. To assess the safety and efficacy of a fixed dose recombinant activated factor VII (rFVIIa; NovoSeven™) in home setting for mild to moderately severe joint, muscle, mucocutaneous bleeding episodes patients with haemophilia A or B inhibitors. Design. Multicentre, open-label, single arm, phase III study one year duration. Methods. Patients their caregivers administered up three doses rFVIIa (90 μg/kg i.v.) at 3 h intervals within 8 onset moderate episode. Once subject...
von Willebrand factor (VWF) is a large, adhesive glycoprotein that biosynthesized and secreted by cultured endothelial cells (EC). Although these constitutively release VWF, they also contain storage pool of this protein can be rapidly mobilized. In study, dense organelle fraction was isolated from umbilical vein centrifugation on self-generated Percoll gradient. Stimulation EC 4-phorbol 12-myristate 13-acetate (PMA) resulted in the disappearance synchronous loss Weibel-Palade bodies as...
Summary Acquired haemophilia A ( AHA ) is a rare bleeding disorder caused by autoantibodies against human factor VIII hFVIII ). OBI ‐1 an investigational, B‐domain deleted, recombinant FVIII , porcine sequence, with low cross‐reactivity to anti‐ antibodies. Efficacy can be monitored activity levels in addition clinical assessments. This prospective, open label, phase 2/3 study was designed evaluate the efficacy of treatment for episodes subjects . After initial dose 200 U kg −1 titrated...
Summary Factor replacement therapy for the treatment of moderate to severe haemophilia A and B can be complicated by production inhibitory alloantibodies factor VIII (FVIII) or IX. Treatment with nanofiltered anti‐inhibitor coagulant complex, Eight Inhibitor Bypassing Activity (FEIBA NF), is a key therapeutic option controlling acute haemorrhages in patients high‐titre inhibitors low‐titre refractory therapy. Given high risk morbidity mortality FVIII FIX, we conducted this Phase 3...
Purpose We present clinical and laboratory data on 18 children from 12 hemophilia treatment centers in the United States, Canada, Europe with purpose of disseminating information regarding a recently recognized, potentially life-threatening complication very young B. Patients Methods Twelve centrs provided concerning who had severe allergic reactions to infused factor (F) IX close association development an inhibitor FIX. Laboratory testing for establishment diagnosis B FIX was done locally...
Summary. The efficacy and safety of an advanced category recombinant antihaemophilic factor produced by a plasma‐ albumin‐free method (rAHF‐PFM) was studied in 111 previously treated subjects with haemophilia A. study comprised randomized, double‐blinded, crossover pharmacokinetic comparison rAHF‐PFM RECOMBINATE rAHF (R‐FVIII); prophylaxis (three to four times per week 25–40 IU kg −1 rAHF‐PFM) for at least 75 exposure days; treatment episodic haemorrhagic events. Median age 18 years, 96% had...